Liraglutide Outperforms Insulin and Placebo for Diabetic Fatty Liver Disease Across 12 Studies | Research

The takeaway

A meta-analysis of 12 studies found liraglutide significantly reduced BMI, triglycerides, and both visceral and subcutaneous fat in T2DM patients with NAFLD, outperforming both placebo and insulin comparators.

−21 cm² visceral fat
Liraglutide significantly reduced the metabolically dangerous fat surrounding organs in diabetic patients with fatty liver disease

What the researchers found

Liraglutide significantly reduced BMI (MD −1.06), triglycerides (MD −0.35 mmol/L), visceral adipose tissue (MD −21.06 cm²), and subcutaneous adipose tissue (MD −20.53 cm²) in T2DM patients with NAFLD across 12 studies.

Why it matters

T2DM and NAFLD together create a vicious cycle of insulin resistance, inflammation, and fat accumulation. Liraglutide breaks this cycle by reducing visceral fat (the metabolically dangerous fat around organs) while improving glucose and lipid parameters — addressing root causes rather than just symptoms.

The numbers in context

12 studies included. 13 outcome measures analyzed. Literature through December 2023.

How the study worked

Systematic review and meta-analysis of 12 studies from PubMed, Web of Science, and NLM databases through December 2023. Compared liraglutide to placebo or other drugs (mainly insulin). Analyzed using Stata 15.1 software.

Who was studied

Patients with T2DM complicated by NAFLD

What this study cannot tell us

The meta-analysis included only 12 studies, with heterogeneous comparator groups (placebo vs insulin vs other drugs). The impact on liver histology (the gold standard for NAFLD assessment) wasn't analyzed. Long-term liver-specific outcomes (fibrosis progression, cirrhosis) weren't captured.

How to read the evidence

Strong evidence from a meta-analysis of 12 studies. Results were consistent and statistically significant across all measured outcomes.

When this study was published

Published in 2024 with literature search through December 2023; represents current evidence for liraglutide in NAFLD.

The bigger picture

NAFLD is becoming the most common chronic liver disease worldwide, and its overlap with diabetes is nearly ubiquitous. GLP-1 agonists are emerging as the treatment of choice for this dual diagnosis because they address multiple pathways simultaneously — glucose control, fat reduction, inflammation, and potentially fibrosis reversal.

Questions still open

Does liraglutide reverse liver fibrosis in patients with advanced NAFLD/NASH?
How does liraglutide compare to semaglutide for NAFLD treatment specifically?
Are the visceral fat reductions sustained long-term after liraglutide discontinuation?

Common questions

Can liraglutide treat fatty liver disease?

This meta-analysis shows liraglutide significantly reduces the fat accumulation (both visceral and subcutaneous) and metabolic dysfunction associated with NAFLD in diabetic patients. While it's not FDA-approved specifically for NAFLD, these results support its use in patients who have both T2DM and fatty liver.

Is liraglutide better than insulin for diabetic patients with NAFLD?

Based on this analysis, yes — liraglutide significantly outperformed insulin (and placebo) in reducing BMI, visceral fat, and triglycerides. Insulin can actually worsen weight gain and fat accumulation, making liraglutide a better metabolic choice for patients with both conditions.

Read the original research

Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.

Endocrine journal, 71(9), 881-894

View on PubMed ↗Publisher’s paper ↗

Citation

Xu, Yuan-Yuan; Wang, Xu; She, Yu-Qing; Liu, Jie; Zhang, Qing. (2024). Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.. Endocrine journal, 71(9), 881-894. https://doi.org/10.1507/endocrj.EJ24-0168